Table 2.
Cancer following diagnosis with PMR
| Prospective cohort with combined cancer cases | ||||||
|---|---|---|---|---|---|---|
| PMR patients | Control patients | |||||
| Study | PMR cases (n) | Cancer cases (n) | Proportion (%) | Controls (n) | Cancer cases (n) | Proportion (%) |
| Muller et al. [57] | 2877 | 667 | 23.18 | 9942 | 1938 | 19.49 |
| Bellan et al. [61] | 100 | 24 | 24.00 | 702 | 41 | 5.84 |
| Ji et al. [45] | 35,918 | 3941 | 10.97 | – | – | – |
| Myklebust et al. [37] | 366 | 34 | 9.29 | 1324 | 143 | 10.80 |
| Haga et al. [32] | 91 | 10 | 10.99 | 794 | 131 | 16.50 |
| Pfeifer et al. [59] | 359 | 66 | 18.38 | 357 | 62 | 17.37 |
| Totala | 39,711 | 4742 | 21.12 | 13,119 | 2315 | 17.65 |
PMR polymyalgia rheumatica
aJi et al. [45] not included in calculation as no control group